Pharma Mar SA (PHMMF)
94.60
0.00 (0.00%)
USD |
OTCM |
Sep 04, 16:00
Pharma Mar Research and Development Expense (Quarterly) : 30.67M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 30.67M |
| March 31, 2026 | 24.43M |
| December 31, 2025 | 29.79M |
| September 30, 2025 | 25.86M |
| June 30, 2025 | 29.67M |
| March 31, 2025 | 22.41M |
| December 31, 2024 | 29.36M |
| September 30, 2024 | 27.14M |
| June 30, 2024 | 25.92M |
| March 31, 2024 | 29.52M |
| December 31, 2023 | 31.17M |
| September 30, 2023 | 25.75M |
| June 30, 2023 | 27.85M |
| March 31, 2023 | 22.59M |
| December 31, 2022 | 26.91M |
| June 30, 2022 | 22.64M |
| March 31, 2022 | 21.35M |
| December 31, 2021 | 29.55M |
| September 30, 2021 | 21.82M |
| June 30, 2021 | 17.12M |
| March 31, 2021 | 17.71M |
| December 31, 2020 | 17.49M |
| September 30, 2020 | 17.38M |
| June 30, 2020 | 11.41M |
| March 31, 2020 | 13.54M |
| Date | Value |
|---|---|
| December 31, 2019 | 9.107M |
| September 30, 2019 | 13.75M |
| June 30, 2019 | 13.06M |
| March 31, 2019 | 16.16M |
| December 31, 2018 | 19.30M |
| September 30, 2018 | 19.18M |
| June 30, 2018 | 24.40M |
| March 31, 2018 | 24.48M |
| December 31, 2017 | 26.93M |
| September 30, 2017 | 22.02M |
| June 30, 2017 | 20.96M |
| March 31, 2017 | 19.07M |
| December 31, 2016 | 22.65M |
| September 30, 2016 | 20.86M |
| June 30, 2016 | 22.53M |
| March 31, 2016 | 20.69M |
| December 31, 2015 | 18.89M |
| September 30, 2015 | 16.76M |
| June 30, 2015 | 16.90M |
| March 31, 2015 | 14.25M |
| December 31, 2014 | 19.18M |
| September 30, 2014 | 17.60M |
| June 30, 2014 | 17.07M |
| March 31, 2014 | 15.57M |
| December 31, 2013 | 14.77M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Oryzon Genomics SA | 6.445M |
| Grifols SA | 99.99M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alkermes Plc | 111.12M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |